SCHEMBL4148244

SCHEMBL4148244

COc1cccc(-c2nc3c(C(=O)Nc4cnccc4C)c(Br)cnc3[nH]2)c1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.63
GSK3A P49840 1/20 0.49
PIN1 Q13526 1/20 0.42
HCRTR1 O43613 1/20 0.42
PARP1 P09874 1/20 0.41
MAPT P10636 2/20 0.40
SIRT2 Q8IXJ6 1/20 0.38
DGAT2 Q96PD7 2/20 0.38
AURKA O14965 1/20 0.38
DYRK1A Q13627 1/20 0.38
SLC9A1 P19634 1/20 0.38
BRAF P15056 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4154232 0.88 GSK3B (0.47) GSK3BGSK3ASIRT2DYRK1ASLC9A1
SCHEMBL4158103 0.86 GSK3B (0.77) GSK3BGSK3APIN1HCRTR1PARP1
SCHEMBL4169267 0.74 GSK3B (0.76) GSK3BGSK3APARP1MEN1NPC1
SCHEMBL4157392 0.74 GSK3B (0.79) GSK3BGSK3AHCRTR1PARP1MAPT
SCHEMBL4157388 0.73 GSK3B (0.59) GSK3BGSK3ADYRK1A
SCHEMBL4152722 0.73 GSK3B (0.60) GSK3BGSK3APIN1PARP1
SCHEMBL4152202 0.71 GSK3B (0.56) GSK3BGSK3A
SCHEMBL4160977 0.71 HPSE (0.41) GSK3BMAPTBRAF
SCHEMBL4154317 0.70 PIN1 (0.57) GSK3BPIN1PARP1AURKASLC9A1
SCHEMBL13778234 0.70 GSK3B (0.55) GSK3BPIN1HCRTR1PARP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885GSK3A 2/4885PIN1 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.